$-0.13 EPS Expected for AxoGen, Inc. (AXGN)

October 14, 2018 - By whatsonthorold

AxoGen, Inc. (NASDAQ:AXGN) Logo

Analysts expect AxoGen, Inc. (NASDAQ:AXGN) to report $-0.13 EPS on November, 7.They anticipate $0.07 EPS change or 116.67 % from last quarter’s $-0.06 EPS. After having $-0.14 EPS previously, AxoGen, Inc.’s analysts see -7.14 % EPS growth. The stock increased 4.65% or $1.51 during the last trading session, reaching $33.98. About 428,867 shares traded. AxoGen, Inc. (NASDAQ:AXGN) has risen 96.73% since October 14, 2017 and is uptrending. It has outperformed by 81.11% the S&P500.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Coverage

Among 3 analysts covering AxoGen (NASDAQ:AXGN), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 3 analyst reports since May 1, 2018 according to SRatingsIntel. As per Tuesday, May 1, the company rating was maintained by JMP Securities. The rating was maintained by Leerink Swann with “Buy” on Tuesday, June 26. Cantor Fitzgerald maintained the shares of AXGN in report on Tuesday, May 1 with “Overweight” rating.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $1.30 billion. The company's surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

AxoGen, Inc. (NASDAQ:AXGN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: